Polina Melamud, APRN
Adult Health · Enfield, CTNPI 1821376740
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 34.2% of the total. Reporting peaked in 2022 at $2,187 and has fallen 62.5% since, to $819 in 2025.
Across 83 payments — averaging $46.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$865
- Astellas Pharma US Inc$295
- Endo Pharmaceuticals Inc.$213
- Axonics, Inc.$207
- Procept Biorobotics Corporation$179
- plus $754 from 11 others
What the payments were for
- Travel & lodging$1,34535%
- Food & beverage$2,21858%
- Education$2567%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 22 | $1,306 |
| Boston Scientific | 9 | $865 |
| Astellas Pharma US Inc | 5 | $295 |
| Endo Pharmaceuticals Inc. | 11 | $213 |
| Axonics, Inc. | 6 | $207 |
| Procept Biorobotics Corporation | 1 | $179 |
| Sumitomo Pharma America, Inc. | 7 | $172 |
| Teleflex LLC | 4 | $129 |
| Rochester Medical Corporation | 4 | $123 |
| Olympus America Inc. | 3 | $86 |
| Myriad Genetic Laboratories, Inc. | 4 | $79 |
| Endo USA, Inc. | 2 | $52 |
| Tolmar, Inc. | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Urovant Sciences Inc | 1 | $22 |
| Coloplast | 1 | $19 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,819 in reported general payments places this provider in the 85th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 86 | $102,012 |
| MyrbetriqMirabegron | 43 | $52,351 |
| Mirabegron ErMirabegron | 12 | $8,386 |
| Tamsulosin Hcl | 435 | $5,793 |
| Potassium Citrate ErPotassium Citrate | 38 | $3,894 |
| Fosfomycin Tromethamine | 11 | $3,524 |
| Finasteride | 232 | $2,432 |
| Silodosin | 50 | $1,915 |
| Solifenacin Succinate | 18 | $882 |
| Dutasteride | 26 | $767 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 74 | $731 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $510 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $333 |
| Oxybutynin Chloride | 12 | $221 |
| Ciprofloxacin Hcl | 51 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $172 | $102,01286 claims |
| Astellas Pharma US IncMyrbetriq | $295 | $52,35143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 418 adult health providers in Connecticut.
Other adult health in Enfield
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.